Division of Nephrology, Columbia VA Health Care System, Columbia, South Carolina, USA.
Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA.
Cardiorenal Med. 2021;11(5-6):226-236. doi: 10.1159/000519014. Epub 2021 Oct 1.
The aim of the study was to determine patterns and predictors of utilization of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) in patients with acute heart failure (AHF) and changes in kidney function at admission, hospitalization, and discharge in relation to clinical outcomes.
This retrospective analysis of the Veterans' Health Administration data (2016) included patients with heart failure (HF) with reduced ejection fraction who were hospitalized. Patients with an estimated glomerular filtration <15 cm3/min/1.73 m2 and those on dialysis were excluded. Patients were categorized based on the use of ACEI/ARB as continued, initiated, discontinued, or no therapy. Multivariable logistic regression evaluated predictors of being discharged home on an ACEI/ARB. Cox regression analysis evaluated outcomes (30 and 180-day mortality/HF readmissions).
3,652 patients were included, of which 37% of patients hospitalized for AHF had ACEI/ARB discontinued on admission, or not initiated. After adjusting for age, blood pressure, and serum potassium, a per-unit increase in admission serum creatinine (SCr) was independently associated with lower rates of continuation or initiation of ACEI/ARB odds ratio 0.51 95% confidence interval (CI) (0.46-0.57). Discharge on ACEI/ARB was independently associated with lower odds of 30- and 180-day mortality hazard ratio (HR) 0.36 95% CI (0.25-0.52), and HR 0.23 95% CI (0.19-0.27), respectively.
Higher SCr at admission is an important determinant of ACEI/ARB being discontinued or withheld in patients admitted with AHF. ACEI/ARB at discharge was associated with lower mortality in patients with AHF.
本研究旨在确定急性心力衰竭(AHF)患者中血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEI/ARB)的使用模式和预测因素,以及入院、住院和出院时肾功能变化与临床结局的关系。
这是对退伍军人健康管理局(2016 年)数据的回顾性分析,纳入了射血分数降低的心力衰竭(HF)住院患者。排除估计肾小球滤过率<15cm3/min/1.73m2 和接受透析的患者。根据 ACEI/ARB 的使用情况,将患者分为继续使用、开始使用、停用或未治疗。多变量逻辑回归评估了出院时继续使用 ACEI/ARB 的预测因素。Cox 回归分析评估了结局(30 天和 180 天死亡率/心力衰竭再入院)。
共纳入 3652 例患者,其中 37%的 AHF 住院患者入院时 ACEI/ARB 被停用或未开始使用。在校正年龄、血压和血清钾后,入院时血清肌酐(SCr)每增加一个单位,继续或开始使用 ACEI/ARB 的可能性降低,比值比为 0.51(95%置信区间[CI]:0.46-0.57)。出院时使用 ACEI/ARB 与 30 天和 180 天死亡率的低可能性独立相关,风险比(HR)分别为 0.36(95%CI:0.25-0.52)和 0.23(95%CI:0.19-0.27)。
入院时 SCr 较高是 AHF 患者 ACEI/ARB 被停用或未使用的重要决定因素。出院时使用 ACEI/ARB 与 AHF 患者的死亡率降低相关。